Abstract
Introduction

Despite the laborious efforts of scientists and the pharmaceutical industry to develop new and more effective antimicrobial therapies, systemic infections remain a serious health issue even in well-developed and wealthy countries of the Western
Hemisphere [1] . This situation is at least partially a result of mechanisms that enable microorganisms to quickly modify their genomes and acquire resistance to newly developed antibiotics [2] . Therefore, the race between drug discovery and the lethal effects of virulent pathogens on millions of patients worldwide seems to be endless.
The problems posed by infectious diseases have become even more serious as a result of the increasing number of patients who are receiving immunosuppressive treatment because of disseminated cancer or organ transplantation. In addition, the significant rise in average life expectancy in recent decades has contributed to an increase in the number of patients suffering from chronic diseases, which increase the vulnerability of these individuals to serious complications of infectious disease [3] . Under these circumstances, an ongoing discussion among scientists and physicians concerning infections and sepsis is both timely and necessary. In this review, we discuss the mechanisms that contribute to sepsis-associated activation of the complement system. Complement constitutes a crucial line of defence against microbial invasion [4] , but it is also often identified as an inducer of excessive inflammatory host responses, which are thought to increase mortality from sepsis [5, 6] .
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• Aetiology-dependent mechanisms of complement activation in sepsis • Sepsis-associated coagulopathy and complement activation • Concluding remarks confirmed infection. SIRS is defined on the basis of clinical criteria, which include body temperature, heart and respiratory rate, blood pCO2 and white blood cell count. Under unfavourable circumstances, sepsis can progress to severe sepsis and ultimately to septic shock. Severe sepsis is a syndrome associated with organ dysfunction, hypoperfusion or hypotension. Septic shock is described as a combination of sepsis-induced hypotension that is unresponsive to adequate fluid resuscitation and the presence of perfusion abnormalities [7] .
According to studies published in 2003, the prevalence of sepsis in the United States was estimated to be approximately 750,000 cases per year [8] . Considering the steady rise in the number of septic patients diagnosed each year, it has been predicted that this number will reach over 1 million cases by 2020. Despite the decrease in sepsis mortality rates over the past 20 years, the increasing number of sepsis cases has resulted in a tripling of the actual number of sepsis-associated deaths, to 215,000 deaths per year; remarkably, sepsis is responsible for 9 .3% of all deaths in the United States [9] . These frightening numbers clearly indicate that the threat of infectious disease is one of the main problems facing twenty-first century medicine.
Contrary to the popular understanding of sepsis biology, which links this syndrome to infection with bacteria, the aetiology of sepsis is actually variable and includes fungi, parasites and viruses as well as bacteria [9] . Sepsis development is often preceded by localized respiratory or abdominal infections, although other organ systems, including the urogenital tract, can also be a source [1] . Currently, Gram-positive organisms outnumber Gram-negative bacteria as causative microflora, and an increasing number of sepsis cases are associated with fungal infections [8] . In a small but appreciable number of patients with a clinical presentation of sepsis, causative organisms cannot be identified [10] [25] . [28] , are opsonized by C3 fragments generated by CRP-induced complement activation and are targeted for phagocytosis [29] .
In evolutionary terms, the alternative pathway is considered to be the oldest pathway of complement activation. Activation of complement through this pathway leads to the formation of a C3 convertase that is significantly different from those formed via the classical and lectin pathways. The internal thioester of C3 is spontaneously hydrolysed (referred to as the 'tickover' of C3) at a slow rate, leading to the formation of C3(H2O), a conformationally altered form of C3. The binding of C3(H2O) to the complement protein factor B changes the conformation of factor B, making it susceptible to cleavage by the constitutively active serum protease factor D into Ba and Bb fragments. These reactions result in the formation of the alternative pathway C3 convertase (C3(H2O)Bb). Like the C4b2a convertase, this complex cleaves C3 into C3a and C3b, with small amounts of C3b binding to the hydroxyl or amino groups on susceptible surfaces; several studies show spontaneous C3b deposition on microorganisms and tumour cells (reviewed in ref. [26]). Surface-bound C3b can bind directly to factor B, and the factor B-C3b complexes can then be cleaved by factor D to form the alternative pathway C3 convertase (C3bBb
Many recently published studies have demonstrated that complement activation can also occur through mechanisms that differ in several aspects from the traditionally recognized pathways of complement activation. For example, a new immunoglobulinindependent mechanism for activation of the classical pathway during S. pneumoniae infection has been described. Complement activation through this mechanism is a result of C1q binding to the C-type lectin SIGN-R1 [30] . This is the first known example of a cell-surface lectin directly initiating the classical pathway. SIGN-R1 is expressed at high levels by macrophages of the spleen marginal zone and lymph nodes [31, 32] and is the principal receptor for the S. pneumoniae capsular pneumococcal polysaccharide (CPS) [33, 34] [47] . Plasmin cleaves iC3b to C3c and C3dg in vitro [48] . In addition, the Hageman factor fragment is capable of inducing complement activation through direct interaction with C1, which activates the C1r and C1s subunits [21] . Incubation of thrombin with C5 leads to C5a generation [49] , and thrombin is also known to stimulate the cleavage of C5 into C5a in vivo [50] . During acute lung inflammation, C5a is produced in C3-deficient mice, which lack C3 cleavage products (i.e. C3b) [50] . It has also been shown that in the absence of C3, thrombin becomes the dominant enzyme during the inflammatory process that generates biologically active C5a.
Thus, in addition to playing an indirect role in regulating the complement pathway through platelet activation, thrombin can directly cleave C5 to initiate the downstream terminal pathway of complement.
The various mechanisms of complement activation described above are summarized in Fig. 1 .
The role of the complement system in the pathogenesis of sepsis
At first glance, the role of complement in sepsis pathogenesis might appear ambiguous or paradoxical: On the one hand, C3 deficiency, which eliminates most complement effector functions, clearly increases sepsis-associated mortality in animals [51-53]; these studies have emphasized the importance of complement as a defence mechanism against invading microbes. Conversely, other data have indicated that inhibition of C5a signalling improves the survival of experimental animals [54]. This apparent inconsistency between various studies may actually be an indication of the diversity of complement functions during the development and progression of sepsis. During the early stages of widespread bacterial infections, complement's pro-inflammatory and antimicrobial properties are critical for protecting the host from the detrimental effects of an uncontrolled spread of microbes, whereas in the later stages of sepsis development, C5a, in concert with cytokines, contributes to the development of multi-organ failure and circulatory insufficiency. The complement system, which was originally viewed as an arm of humoural immunity, is now perceived as a central constituent of innate immunity, defending the host against infections, orchestrating inflammatory responses and connecting the innate and adaptive immune responses [5]. This broad spectrum of complement activities, together with the abundance of complement proteins in the plasma, enables this system to cope with local and systemic infections. In addition to plasma proteins that interact with various cells and mediators of the immune system, several membrane-bound regulators and receptors constitute an efficient regulatory module of the complement system that is designed to limit the activation of complement to pathogen surfaces or altered host cells [55]. The anti-microbial properties of complement can be divided into three distinct categories: (i ) opsonization and subsequent killing of microorganism by phagocytes, (ii ) lysis of pathogens (Neisseria species) and (iii ) coordination of inflammatory events associated with the response to infection [4]. Opsonization involves the coating of bacterial surfaces with complement proteins such as C3b and iC3b. These cleavage products of C3 are covalently bound to the pathogen surfaces and act as ligands for receptors expressed by phagocytes. Engagement of these receptors with their ligands significantly facilitates the phagocytosis and killing of bacteria by neutrophils and macrophages [25]. Various defects in opsonization are known to contribute to an increased susceptibility to infections caused by pyogenic bacteria such as
Haemophilus influenzae and S. pneumoniae [25] . Lysis of pathogens occurs as a result of sequential activation of complement proteins on pathogen surfaces, forming the MAC, which then creates pores in the bacterial cell wall and ultimately leads to bacterial lysis [5] . Although A [29] .
crucial requirement for successful sepsis therapy is the capacity to break this vicious cycle of progressive infection and exacerbating inflammation. The most effective way to do so is through elimination of the infectious agent. In many cases, therapy based on the empiric selection of antibiotics is sufficient to prevent severe sepsis complications. However, early surgical intervention is also critical in controlling and eliminating the focus of infection if sepsis is related to perforation or obstruction of the
Fig. 1 Activation of the complement system. (A) C1 can bind to various factors to initiate the classical pathway (CP). These include, most commonly, antibody-antigen complexes, but also danger-associated molecular patterns (DAMPs) such as membrane fragments and proteins associated with tissue damage. C1 also binds to C-reactive protein (CRP) and serum amyloid protein (SAP), which recognize pathogen-associated molecular patterns (PAMPs) present on the surfaces of many pathogens. Binding by the C1q subunit of C1 activates C1r and C1s, which results in the cleavage of C2 and C4 by C1s (i ). Binding of mannose-binding lectin (MBL) or ficolins to PAMPs or apoptotic host cells activates MBL-associated serine proteases (MASPs), which cleave C4 (ii ). The result of activation through either pathway is that C4a is released and C2a and C4b form the CP C3 convertase on the surface of the pathogen or apoptotic cell (iii ), resulting in cleavage of C3 into C3a and C3b fragments. The alternative pathway (AP) can be initiated by spontaneous hydrolysis of C3 ('tickover') to form C3(H2O) (iv ). C3(H2O) binds to factor B (fB), which is cleaved by factor D (fD) into Ba and Bb fragments, resulting in formation of the initial AP C3 convertase (v). Like the CP convertase, the AP C3 convertase cleaves C3 into C3a and C3b. The anaphylatoxin C3a induces chemotaxis and inflammation, while some C3b binds to the cell surface (opsonization) (vi ), which promotes phagocytosis by CR3-bearing cells. Surface-bound C3b binds to factor B, and the resulting complex is cleaved by factor D to form the AP C3 convertase (vii ). This convertase is stabilized by the binding of properdin (P). Through an amplification loop, the AP C3 convertase cleaves more C3 to augment complement activation induced by the classical or lectin pathways (viii ). (B) After C3 is cleaved by the CP C3 convertase, C3b binds to the cell surface but also can bind to the C4b2a complex to form the CP C5 convertase (i ). Similarly, C3b resulting from activity of the AP C3 convertase can bind to C3bBbP to form the AP C5 convertase (ii ). These convertases cleave C5, leading to the generation of C5a, which acts similarly to C3a to promote inflammation and chemotaxis, and C5b. C5b is bound by C6 and C7, which can insert into the cell membrane and bind C8. One or multiple C9 molecules then bind, resulting in formation of the membrane attack complex (MAC) (iii ). (C) C1 can bind to SIGN-R1 on marginal zone macrophages to result in formation of the CP C3 convertase, and subsequent C3 cleavage (i ). P can bind directly to C3b through interaction with Neisseria lipo-oligosaccharide (LOS) and, in the presence of fB and fD, can form the AP C3 convertase (ii ). P from neutrophils can bind to early apoptotic T cells to activate the AP and initiate C3b deposition, facilitating phagocytosis (iii ). Phagocytosis can also be promoted through a direct interaction of P with phagocytes (without complement activation) when it binds to T cells (iv ). (D) C1 can interact with the Hageman factor fragment, which results in complement activation through the CP (i ). Thrombin induces C3 cleavage through the CP through the activation of platelets (ii ). Activated platelets release a serine/threonine (ser/thr) kinase that can phosphorylate (p) C3b to block its cleavage into iC3b by Factor I (fI) (iii ). Plasmin can directly cleave iC3b into C3c and C3dg (iv
Sepsis-associated coagulopathy and complement activation
Coagulation is generally activated during the course of sepsis [65] . Sepsis-associated coagulopathy can occur in various forms, including disseminated intravascular coagulation (DIC), a particularly severe complication that significantly and adversely affects the prognosis in sepsis [66] . DIC is a condition in which an increased tendency toward coagulation leads to the formation of multiple thrombi in the microcirculation. This massive formation of thrombi is responsible for the consumption of clotting factors, which in turn leads to haemorrhagic diathesis [67] [39] . Several studies have demonstrated that complement activation can be triggered by the activation of the coagulation or contact systems [40] , as described in the previous section of this review. Thus, cross-talk between the coagulation and complement systems represents another way of amplifying complement activation in sepsis. 
Concluding remarks
